(Q41704925)

7 October 2017

1 reference

title

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview (English)

1 reference

7 October 2017

phase II clinical trial

0 references

1 reference

1 reference

4

1 reference

7 October 2017

S B Kaye

1

1 reference

7 October 2017

M Piccart

series ordinal

2

1 reference

7 October 2017

M Aapro

series ordinal

3

1 reference

7 October 2017

J Kavanagh

series ordinal

5

1 reference

7 October 2017

1 November 1997

1 reference

European Journal of Cancer

7 October 2017

1 reference

7 October 2017

33

1 reference

7 October 2017

2167-2170

1 reference

7 October 2017

13

1 reference

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

7 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Coping with toxicities of docetaxel (Taxotere)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900363-8

7 January 2021

10.1016/S0959-8049(97)00363-8

Identifiers

DOI

1 reference

7 October 2017

1 reference